19th week of 2012 patent applcation highlights part 51 |
Patent application number | Title | Published |
20120115721 | COMPOSITION AND METHOD FOR CONTROLLING PESTS - The present invention provides a composition comprising, as active ingredients, 4-oxo-4-[(2-phenylethyl)amino]-butyric acid and fipronil; a method of controlling pests, which comprises applying effective amounts of 4-oxo-4-[(2-phenylethyl)amino]-butyric acid and fipronil to a plant or growing site of plant and so on. | 2012-05-10 |
20120115722 | MIXTURES OF MESOIONIC PESTICIDES - Disclosed are compositions comprising (a) at least one compound selected from compounds of Formula 1, N-oxides, and salt thereof, | 2012-05-10 |
20120115723 | Ballast Water Treatment System - A composition for treating waters, e.g. ballast water or injection water for oil recovery, to kill in-situ aquatic invasive species comprises at least one biocide capable of killing both animal and plant micro-organisms. The at least one biocide preferably comprises Brilliant Green, Gentian Violet, and/or erythrosine, and a wetting agent or detergent-like compound such as CTAB or CTAC. The invention also relates to a system for treating ballast water in situ comprising means for injecting a composition for treating ballast water; means for measuring the flow rate or amount of ballast water to be treated; means for controlling the dosing of the composition; and means for storing or receiving the composition. The invention also relates to a method of detecting viable aquatic organisms in ballast water in situ comprising detecting metabolism in viable micro-organisms in ballast water and, therefore, measuring the efficacy of any treatment. | 2012-05-10 |
20120115724 | METHOD OF CONTROLLING UNDESIRED VEGETATION - The present invention relates to methods of controlling undesired plant growth in crops of soya through the use of certain substituted pyrimidine derivatives. It also relates to certain novel substituted pyrimidine derivatives. Effective weed control is thereby obtained, whilst at the same time achieving unexpected levels of crop safety. | 2012-05-10 |
20120115725 | SYNERGISTIC COMBINATION OF FLUMETSULAM WITH THIABENDAZOLE - A synergistic antimicrobial composition containing flumetsulam and thiabendazole. | 2012-05-10 |
20120115726 | HERBICIDAL COMPOUNDS - The present invention relates to 6,6-dioxo-6-thia-1,4-diaza-naphthalene derivatives of formula (I) where R | 2012-05-10 |
20120115727 | CONTROL OF PHENOXYALKANOIC ACID HERBICIDE-RESISTANT WEEDS WITH 4-AMINO-3-CHLORO-6-(4-CHLORO-2-FLUORO-3-METHOXYPHENYL)PYRIDINE-2-CARBOXYL- IC ACID AND ITS SALTS OR ESTERS - 4-Amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid and its salts or esters effectively controls phenoxyalkanoic acid herbicide-resistant weeds despite having the same mode of action as phenoxyalkanoic acid herbicides. | 2012-05-10 |
20120115728 | COMPOSITIONS CONTAINING ANTHRAQUINONE DERIVATIVES AS GROWTH PROMOTERS AND ANTIFUNGAL AGENTS - Compositions for modulating plant growth, seed germination and soil borne diseases comprising anthraquinone derivatives are disclosed. | 2012-05-10 |
20120115729 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS - Disclosed is a process for forming films, fibers, and beads comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally occurring and/or synthetic polymer. Disclosed herein are the films, fibers, and beads obtained from the disclosed process. This Abstract is presented solely to aid in searching the subject matter disclosed herein and is not intended to define, limit, or otherwise provide the full scope of the disclosed subject matter. | 2012-05-10 |
20120115730 | Agricultural Compositions - Described are agrochemical compositions comprising alkoxylation products according to general formula (I) | 2012-05-10 |
20120115731 | METHOD FOR PREPARING YTTRIUM BARIUM COPPER OXIDE (YBCO) SUPERCONDUCTING NANOPARTICLES - A method for preparing yttrium barium copper oxide (“YBCO”; “Y-123”; YBa | 2012-05-10 |
20120115732 | SUPERCONDUCTOR WINDING - This invention relates to a superconducting electrical machine, comprising: a superconducting winding at least partially surrounded by a magnetic flux guide, wherein the magnetic flux guide includes a binder loaded with a magnetic material. | 2012-05-10 |
20120115733 | SUPERCONDUCTOR DEVICE - This invention relates to a superconductor device, comprising: a superconductor; a former which supports the superconductor; and, an intermediate electrical connector attached to the former for coupling the superconductor to a power source, wherein the intermediate electrical connector is connected to the superconductor via a deformable portion in the intermediate electrical connector, wherein the deformable portion allows relative movement between the superconductor and former. | 2012-05-10 |
20120115734 | IN SILICO PREDICTION OF HIGH EXPRESSION GENE COMBINATIONS AND OTHER COMBINATIONS OF BIOLOGICAL COMPONENTS - Various systems and methods for selecting candidate biological components and/or combinations of biological components that affect a biological process are described. For example, a computing device may use a computer model to simulate the biological process and predict a phenotypic outcome. In this manner, the impact of candidate components and combinations may be determined using the computer model. The computing device may determine optimal characteristics such as expression levels of biological components that result in a desirable phenotypic outcome of the biological process as predicted by the computer model. The computing device may perform sensitivity analysis around the optimal characteristics. The sensitivity analysis may be used to determine whether the candidate combinations are robust across a range of the optimal characteristics. The computing device may select various candidate components and combinations based on the sensitivity analysis and the predicted phenotypic outcome. | 2012-05-10 |
20120115735 | Pathways Underlying Pancreatic Tumorigenesis and an Hereditary Pancreatic Cancer Gene - There are currently few therapeutic options for patients with pancreatic cancers and new insights into the pathogenesis of this lethal disease are urgently needed. To this end, we performed a comprehensive analysis of the genes altered in 24 pancreatic tumors. First, we determined the sequences of 23,781 transcripts, representing 20,583 protein-encoding genes, in DNA from these tumors. Second, we searched for homozygous deletions and amplifications using microarrays querying ˜one million single nucleotide polymorphisms in each sample. Third, we analyzed the transcriptomes of the same samples using SAGE and next-generation sequencing-by-synthesis technologies. We found that pancreatic cancers contain an average of 63 genetic alterations, of which 49 are point mutations, 8 are homozygous deletions, and 6 are amplifications. Further analyses revealed a core set of 12 regulatory processes or pathways that were each genetically altered in 70% to 100% of the samples. The data suggest that dysregulation of this core set of pathways is responsible for the major features of pancreatic tumorigenesis. | 2012-05-10 |
20120115736 | NUCLEIC ACID SEQUENCE ANALYSIS - Provided are methods for sequencing a nucleic acid with a sequencing enzyme, e.g., a polymerase or exonuclease. The sequencing enzyme can optionally be exchanged with a second sequencing enzyme, which continues the sequencing of the nucleic acid. In certain embodiments, a template is fixed to a surface through a template localizing moiety. The template localizing moiety can optionally anneal with the nucleic acid and/or associate with the sequencing enzyme. Also provided are compositions comprising a nucleic acid and a first sequencing enzyme, which can sequence the nucleic acid and optionally exchange with a second sequencing enzyme present in the composition. Compositions in which a template localizing moiety is immobilized on a surface are provided. Also provided are methods for using data from analytical reactions wherein two different enzymes are employed, e.g., at a same or different reaction regions. | 2012-05-10 |
20120115737 | RESTRICTION ENDONUCLEASE ENHANCED POLYMORPHIC SEQUENCE DETECTION - Provided is an improved method for the detection of specific polymorphic alleles in a mixed DNA population. The method comprises enriching the relative percentage of a given polymorphic allele that is exponentially amplifiable by PCR. Also provided are methods for selectively enriching target nucleic acid, for example, fetal nucleic acid in a maternal sample. In the case of detecting fetal nucleic acid in a maternal sample, a restriction enzyme is introduced that can discriminate between the alleles of a polymorphic site. Preferably, the maternal allele is digested and nucleic acid comprising the paternal allele is relatively enriched. | 2012-05-10 |
20120115738 | Integrated Microfluidic Device and Methods - A microfluidic device for analyzing a sample of interest is provided. The microfluidic device can comprise a microfluidic device body, wherein the microfluidic device body comprises a sample preparation area, a nucleic acid amplification area, a nucleic acid analysis area, and a network of fluid channels. Each of the sample preparation area, the nucleic acid amplification area and the nucleic acid analysis area are fluidly interconnected to at least one of the other two areas by at least one of the fluid channels. Using the microfluidic device, sample preparation can be combined with amplification of a biologically active molecule, and a suitable biological sample can be provided for analysis and/or detection of a molecule of interest. The small-scale apparatus and methods provided are easier, faster, less expensive, and equally efficacious compared to larger scale equipment for the preparation and analysis of a biological sample. | 2012-05-10 |
20120115739 | ASSAY FOR ANTI-EGFRvIII ANTIBODIES - Detection of human antibodies directed against the tumor-specific protein Epidermal Growth Factor Receptor variant Class III (EGFRvIII) provide information on tumor burden and vaccine response. The methods of the invention permit the specific identification of antibodies that are able to bind to EGFRvIII. The methods are useful in determining the presence of an EGFRvIII-expressing tumor and in detecting immune responses following immunization with EGFRvIII-derived peptide as part of a cancer immunotherapy regimen. | 2012-05-10 |
20120115740 | BACTERIAL STRAIN IDENTIFICATION METHOD AND SYSTEM - Methods for identifying bacterial strains by using sets of distributed genes that are present in some but not all strains of a given species, associated methods for treating bacterial infections are disclosed. The methods may include examining a sample of a bacterial species, selecting a strain of interest based on possession of a unique genetic characteristic that is present in only the strain of interest and not in the other strains, examining the distributed genes possessed by the strain of interest, and detecting gene-possession variation in the distributed genes of the sample strains as compared to genes of known strains. | 2012-05-10 |
20120115741 | Reagents For The Atherosclerotic Coronary Plaque And Uses Thereof - The present invention discloses antibodies or fragments thereof able to bind isolated coronary plaque samples and processes for their production using host cells containing DNA sequences encoding for said antibodies of fragments thereof. Methods for screening ligands to said isolated samples are also described, and compositions containing said antibodies are also provided. | 2012-05-10 |
20120115742 | METHODS FOR IDENTIFICATION - The invention relates to methods for the discovery of new chemical entities and pharmaceutical compositions with broad-spectrum chemokine inhibitor (BSCI) activity, together with the use of such agents as anti-inflammatory medicaments. In one aspect, there is provided a method for the identification of a compound or agent with BSCI activity comprising the steps of (a) firstly one or more candidate compounds or agents are screened for binding to a somatostatin receptor such as the type 2 somatostatin receptor (sstr2); then (b) compounds or agents which show binding to the somatostatin receptor are tested for BSCI activity in a functional assay. | 2012-05-10 |
20120115743 | COMPOSITIONS AND METHODS FOR CLASSIFYING THYROID NODULE DISEASE - A system for classifying thyroid nodule tissue as malignant or benign is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated to with either malignant or benign thyroid nodule disease. The thyroid classification system provides for sets of “thyroid classifying” target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying thyroid nodule tissue. | 2012-05-10 |
20120115744 | METHODS FOR GENERATING TARGET SPECIFIC PROBES FOR SOLUTION BASED CAPTURE - Provided herein are compositions and kits for single-stranded nucleic acid probes, and methods for making the single-stranded nucleic acid probes, where the single-stranded nucleic acid probes comprise a probe region having a predetermined sequence which is flanked by a 5′ region having a first restriction enzyme recognition sequence and flanked by a 3′ region having a second restriction enzyme recognition sequence, and a region which hybridizes to a capture nucleic acid molecule. The single-stranded nucleic acid probes are useful for solution-based capture methods. | 2012-05-10 |
20120115745 | METHODS FOR PREDICTING SENSITIVITY TO TREATMENT WITH A TARGETED TYROSINE KINASE INHIBITOR - The present disclosure relates generally to the evaluation and/or treatment of a subject having or suspected of having a neoplastic condition, and in particular to the use of biomarkers for identifying patients receptive to a certain drug therapy, and which permit monitoring of patient response to such therapy. | 2012-05-10 |
20120115746 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING IRRITABLE BOWEL SYNDROME - Compositions and methods for diagnosing and treating CVH and CVH-associated disorders are disclosed. Genes differentially expressed in CVH tissues relative to normal tissues are identified. The genes and the gene products (i.e., the polynucleotides transcribed from and polypeptides encoded by the genes) can be used as markers of CVH. The genes and the gene products can also be used to screen agents that modulate the gene expression or the activities of the gene products. | 2012-05-10 |
20120115747 | Methods Of Renal Cancer Detection - Disclosed are methods for detecting, diagnosing or monitoring a renal cancer in a subject. The methods include detecting quantity of one or more polypeptides or fragments thereof comprised by body fluid such as urine, wherein the one or more polypeptides or fragments thereof, can be present at elevated levels in a subject with a kidney cancer, as compared to a subject without a kidney cancer. Non-limiting examples of such polypeptides include aquaporin-1, adipose differentiation-related protein and paired box protein-2. Antibody probes can be used to detect or quantify the polypeptides. In some embodiments, mass spectroscopy can be used to detect or quantify the polypeptides, or to identify a polypeptide in a body fluid sample from a subject with a kidney cancer. | 2012-05-10 |
20120115748 | METHODS FOR MAKING AND USING SPR MICROARRAYS - An article, process, and method for surface plasmon resonance plates are described. A substrate is covered with a thin metal film onto which a second thin metal film is deposited. The surface of the second thin metal film is converted to the metal oxide which is used to covalently bond organosilanes to the surface. Reactive organosilanes containing terminal bonding groups are arranged in a plurality of spots that are surrounded by inert organosilanes. Biomolecule attachment to the binding group is detected or measured from surface plasmon signals from the first thin metal film. | 2012-05-10 |
20120115749 | Tumour Markers - A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient. | 2012-05-10 |
20120115750 | Expression of FABP4 and Other Genes Associated with Bladder Cancer Progression - Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4AI, UBE2C, BIRC5, COLI8A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer. | 2012-05-10 |
20120115751 | METHOD OF PREPARING AN ADDUCT - A method for identifying one or several molecular structure(s) having a high-affinity for a target of interest, the molecular structure(s) each including one nucleotide chain onto which is hybridized at least one PNA-encoded molecule. | 2012-05-10 |
20120115752 | Method for Generating Aptamers with Improved Off-Rates - The present disclosure describes the identification and use of aptamers and photoaptamers having slower dissociation rate constants than those obtained using previously described methods. Specifically, the present disclosure describes methods for the identification and use of aptamers to one or more targets within a histological or cytological sample, which have slow rates of dissociation. The aptamers may be used to assess localization, relative density, and presence or absence of one or more targets in cytological and histological samples. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. The aptamers may also be used to introduce target specific signal moieties. In addition to target identification, the aptamers may be used to amplify signal generation through a variety of methods. | 2012-05-10 |
20120115753 | Method for Drug Screening For Agents for the Treatment of Hepatitis C Virus Infection - The present invention describes an improved method of screening of anti HCV agents that may have an efficacy for treatment of hepatitis C virus. The invention includes cryogenic hepatocyte bank, wherein the bank includes multiple hepatocytes collected from multiple HCV patients and the hepatocyte bank includes more than one genotype of HCV. The method involves the isolation and cryopreservation of HCV infected hepatocytes from multiple infected individuals. The isolated and cryopreserved hepatocytes are stored in a cryopreservation bank. These stored hepatocytes then are cultured in a culture medium, and anti-HCV screening of the hepatocytes is done by subjecting HCV infected hepatocytes in parallel to action of different anti-HCV compounds at various concentrations. Effective anti-HCV agents will lead to a decrease in HCV content in the cultures. | 2012-05-10 |
20120115754 | METHOD FOR DIAGNOSING AND/OR TYPING RENAL CELL CARCINOMA - The present invention relates to a method for diagnosing, typing and/or subtyping renal cell carcinoma as well as predicting the response to medication of patients suffering from renal cell carcinoma. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients. | 2012-05-10 |
20120115755 | MICROFLUIDIC MAGNETOPHORETIC DEVICE AND METHODS FOR USING THE SAME - A microfluidic device may employ one or more sorting stations for separating target species from other species in a sample. The separation is driven by magnetophoresis. A sorting station generally includes separate buffer and sample streams. A magnetic field gradient applied to the sorting station deflects the flow path of magnetic particles (which selectively label the target species) from a sample stream into a buffer stream. The buffer stream leaving the sorting station is used to detect or further process purified target species labeled with the magnetic particles. | 2012-05-10 |
20120115756 | ACOUSTICALLY MEDIATED FLUID TRANSFER METHODS AND USES THEREOF - Invention methods employ the use of acoustic waves to transfer small amounts of fluid in a non-contact manner. In invention methods, acoustic waves are propagated through a separated pool of a source fluid in such a manner that causes the ejection of a single micro-droplet from the surface of the pool. The droplet is ejected towards a target with sufficient force to provide for contact of the droplet with the target. Because the fluid is not contacted by any fluid transfer device such as a pipette, the opportunities for contamination are minimized. Invention methods may be employed to transfer fluids from an array of source sites to an array of target sites, thereby enabling the precision automation of a wide variety of procedures including screening, and synthesis procedures commonly used in biotechnology. | 2012-05-10 |
20120115757 | SELF-SENSING ARRAY OF MICROCANTILEVERS FOR CHEMICAL DETECTION - The invention provides a chemical detection system for detecting at least one target chemical species, including a self-sensed cantilevered probe array having a plurality of self-sensed cantilevered probes, at least one chemical-sensitive coating material applied to at least one cantilevered probe in the cantilevered probe array, and an interface circuit that is coupled to the cantilevered probe array. At least one cantilevered probe in the cantilevered probe array exhibits a shifted cantilevered probe response when the cantilevered probe array is exposed to the target chemical species and the interface circuit actuates the cantilevered probe. A handheld chemical detection system and a method of operation are also disclosed. | 2012-05-10 |
20120115758 | METHODS USING FORMATE GELS TO CONDITION A PIPELINE OR PORTION THEREOF - A gelled composition for pipeline, flowline, pipeline jumper or flowline jumper dewatering or preventing ingress of seawater into open pipeline systems or components during tie-in operations of jumpers or additional pipe, valving, manifolds, subsea pipeline architecture or flow conduits operations is disclosed, where the composition includes a concentrated metal formate solution and a hydratable polymer. The gelled formate compositions have improved dewatering properties with 100% or 360 pipe coverage. The gelled formate compositions have can also be reused by breaking and reformulation. | 2012-05-10 |
20120115759 | TREATMENT FLUIDS CONTAINING A BORON TRIFLUORIDE COMPLEX AND METHODS FOR USE THEREOF - Treatment fluids for use in subterranean formations, particularly sandstone and other siliceous formations, may contain a source of fluoride ions to aid in mineral dissolution. In some cases, it may be desirable to generate the fluoride ions from a fluoride ion precursor, particularly a hydrofluoric acid precursor, such as a boron trifluoride complex. Methods described herein can comprise providing a treatment fluid that comprises an aqueous base fluid, a boron trifluoride complex, and a chelating agent composition, and introducing the treatment fluid into a subterranean formation, | 2012-05-10 |
20120115760 | HARD COATING FILM, MATERIAL COATED WITH HARD COATING FILM, AND DIE FOR COLD PLASTIC WORKING - Disclosed herein are a hard coating film, a material coated with the hard coating film, and a die for cold plastic working, the coating film excelling conventional surface coating layers in wear resistance as well as slidability with a low frictional coefficient. | 2012-05-10 |
20120115761 | Lubricating Composition Containing a Malic Acid Derivative - The invention relates to a lubricating composition containing (a) an N-substituted malimide, and (b) an oil of lubricating viscosity. The invention further provides for the use of the lubricating composition for lubricating a limited slip differential. | 2012-05-10 |
20120115762 | Process for Making Basestocks from Renewable Feedstocks - A process for converting feedstock triglycerides to lube basestocks. The process has the steps of (a) metathesizing the feedstock triglycerides with ethylene in the presence of a metathesis catalyst to form alpha olefins and medium-chain triglycerides and (b) hydroisomerizing the medium-chain triglycerides in the presence of a hydroisomerization catalyst and hydrogen to form methyl-branched triglycerides. The alpha olefins may be oligomerized in the presence of an oligomerization catalyst to form poly(alpha olefins). | 2012-05-10 |
20120115763 | LUBRICANT COMPOSITIONS BASED ON BLOCK COPOLYMERS AND PROCESSES FOR MAKIN - Provided are lubricant compositions with improved oxidative stability and frictional and wear resistance properties for use in engine oil applications. The lubricant compositions include: i) a first base stock selected from a Group I base stock, a Group II base stock or a combination thereof at 50 to 80 wt %; ii) a block copolymer at 1 to 10 wt %; iii) a viscosity modifier at 3 to 15 wt % selected from polymers and copolymers of methacrylate, butadiene, olefins and alkylated styrenes; and iv) an additive package including a combination of antioxidants, dispersants, detergents, friction modifiers and antiwear agents at 2 to 30 wt %. | 2012-05-10 |
20120115764 | MACROMOLECULAR AMINE-PHENOLIC ANTIOXIDANT COMPOSITIONS, PROCESS TECHNOLOGY THEREOF, AND USES THEREOF - This invention relates to novel macromolecular amine-phenolic compositions having oxidation inhibition characteristics that are exhibited when added to organic material normally susceptible to oxidative degradation in the presence of air or oxygen, such as petroleum products, synthetic polymers, and elastomeric substances. | 2012-05-10 |
20120115765 | USE OF ALKANOLAMINES BASED ON PROPYLENE OXIDE AS ADDITIVES IN LUBRICANTS - A lubricant which comprises an alkanolamine of the formula I | 2012-05-10 |
20120115766 | DEGREASING COMPOSITION AND PRODUCTION METHOD THEREOF - As a method for producing a degreasing composition in the form of a slurry, crystallization of the composition during low-temperature storage being suppressed and the composition being used for preparing a cleaning liquid having little environmental impact, provided is a method including a step of obtaining a slurry by mixing a first liquid and a powdery silicate having a particle diameter ranging from 0.2 mm to 10 mm, wherein the first liquid contains an alkaline component composed of at least one of sodium hydroxide and potassium hydroxide, an alcohol having three or fewer carbon atoms, and water; and the degreasing composition contains, with respect to the total composition, 10 mass % to 60 mass % of the alkaline component, 0.1 mass % to 5 mass % of the alcohol, 1 mass % to 50 mass % of the silicate, and 20 mass % to 50 mass % of water including hydration water of the silicate, and contains no chelating agent. | 2012-05-10 |
20120115767 | Oxidizing Bleach Composition - The invention provides an aqueous bleaching solution for substrate treatment. The aqueous bleaching solution features a source of oxidant and a plurality of optically functional nanoparticles. The optically functional nanoparticles are nanoparticles in the range of about 0.1 nanometers to about 400 nanometers in size. The aqueous bleaching solution may optionally include one or more an oxidant-stable surfactants and optionally, one or more oxidant-stable polymers, and adjuncts. The optically functional nanoparticles are extremely stable in the aqueous bleaching solution and remain substantially suspended in the aqueous bleaching solution due to their extremely small size despite having an average density greater than that of the bleaching solution. The optically functional nanoparticles provide at least one optical functional benefit to the bleaching solution owing to their uniform and stable suspension throughout the solution, including such benefits as uniform light absorption, light and radiation scattering, fluorescent emission, phosphorescent emission, coloration, and visual aesthetic benefits and the like. Further, optically functional benefits include those benefits provided to a substrate or surface treated with the aqueous bleaching solutions whereby the optically functional property is transferred either temporarily or permanently to the substrate or surface following contact with bleaching solutions containing the optically functional nanoparticles. | 2012-05-10 |
20120115768 | LIQUID DETERGENT COMPOSITION - The present invention provides a liquid detergent composition containing a specific amount of surfactant (A); a specific amount of a polymer compound (B) having the polyether chain moiety (i) and the polymer chain moiety (ii) composed of polymerization units derived from the specific unsaturated monoethylenic monomer; and water, wherein component (A) contains a specific amount of a specific alkoxyl nonionic surfactant (a1), and component (B) is a polymer compound having the polyether chain moiety (i) composed of polymerization units derived from an epoxide having 2 to 5 carbon atoms and the polymer chain moiety (ii) composed of polymerization units derived from one or more unsaturated carboxylic acid monomers selected from acrylic acid, methacrylic acid and maleic acid, the polymer compound having a graft structure wherein one of the chain moieties (i) and (ii) is the main chain and the other is a side chain. | 2012-05-10 |
20120115769 | DETERGENT COMPOSITION - The present invention relates to the detergent composition, containing (a) a nonionic surfactant represented by the formula (1); and (b) a sulfuric acid ester salt represented by the formula (2): | 2012-05-10 |
20120115770 | FATTY ACID ALKYL ESTER SULFONATE METAL SALT POWDER MIXTURE AND METHOD FOR PRODUCING THE SAME - The invention provides a fatty acid alkyl ester sulfonate metal salt mixture of (a) a fatty acid alkyl ester sulfonate metal salt having an endothermic peak area at 50 to 130° C. of less than 50% relative to the whole endothermic peak area at 0 to 130° C. as measured on a differential scanning calorimeter, and (b) a fatty acid alkyl ester sulfonate metal salt having an endothermic peak area at 50 to 130° C. of 50% or more relative to the whole endothermic peak area at 0 to 130° C. as measured on a differential scanning calorimeter, with a ratio of (a) to (b) by mass of 95/5 or less. The mixture of the invention is excellent in anti-caking properties. | 2012-05-10 |
20120115771 | CARRIER - A pharmaceutical composition is provided comprising a vitamin E derivative, an anionic phopholipid-binding protein, an anionic phospholipid and a sterol. Also provided is a method for preparing a composition for delivering a cargo to a subject comprising a) forming liposomes from a vitamin E derivative, an anionic phospholipid-binding protein such as annexin, an anionic phospholipid such as phosphatidylserine and a sterol; and b) encapsulating the cargo in the liposomal composition. | 2012-05-10 |
20120115772 | CONJUGATION METHOD - A process for the conjugation of a polymer to a protein, which comprises reacting a polymeric conjugating agent with said protein, in an aqueous medium, in the presence of an amphipathic sugar polymer. The process is particularly useful when conjugating PEG to proteins, particularly to proteins which have previously proved difficult to PEGylate in acceptable yields, for example INF-β. | 2012-05-10 |
20120115773 | MODIFIED OMCI AS A COMPLEMENT INHIBITOR - The method of the invention relates to a modified OmCI polypeptide or a polynucleotide encoding a modified OmCI polypeptide which lacks LK/E binding activity and the use of such polypeptides and polynucleotides for the treatment of a disease or condition mediated by complement. | 2012-05-10 |
20120115774 | ANTIMICROBIAL CATIONIC LIPO-BETA-PEPTIDES - In some aspects, the present invention provides ultrashort lipopeptides which feature β-amino acids or β-peptides and demonstrate antimicrobial activity. Accordingly, some aspects of the present invention provide lipopeptide compositions and methods of making and using the compositions as antimicrobial agents. | 2012-05-10 |
20120115775 | MUTANT TAT PROTEINS AND USES THEREOF - Disclosed are viral proteins associated with Human Immunodeficiency Virus (HIV) infections and mutants thereof, particularly, mutant Tat proteins capable of modulating multiple steps of the HIV-1 replication cycle. Also provided are methods of using the mutant Tat proteins, and pharmaceutical compositions comprising the same, for prevention and treatment of HIV-1 infections, and/or symptoms associated therewith. | 2012-05-10 |
20120115776 | ADIPONECTIN-CONTAINING EATING BEHAVIOR CONTROL AGENT FOR ORAL ADMINISTRATION - Disclosed is a technique that facilitates the oral ingestion of adiponectin in a large quantity and enables the expansion of the range of use applications of adiponectin. Specifically disclosed is an appetite control agent for oral administration, which comprises adiponectin as an active ingredient. Particularly, the appetite control agent comprises a transformant capable of expressing adiponectin. Also specifically disclosed is a food composition for controlling appetite, which comprises the appetite control agent. | 2012-05-10 |
20120115777 | Use of Ultrarapid Acting Insulin - Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day. | 2012-05-10 |
20120115778 | Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2 - Methods for treating eating disorders associated with excessive weight gain, suppressing appetite, reducing body weight, or treating obesity in an animal by administering one or more antagonists of the serotonin Htr1a or Htr2b receptor, or a Tph2 inhibitor are provided, or combinations thereof. | 2012-05-10 |
20120115779 | AGENT FOR SUPPRESSING ELEVATION OF BLOOD TRIGLYCERIDE CONCENTRATION - An agent for suppressing elevation of a blood triglyceride concentration, comprising a polyglutamic acid as an active ingredient. | 2012-05-10 |
20120115780 | Porogen Containing Calcium Phosphate Cement Compositions - Porogen containing calcium phosphate cement compositions are provided. Aspects of the cement compositions include a dry calcium phosphate reactant component, a setting fluid component and a porogen component. The porogen component includes at least first and second porogens having different pore forming profiles. Aspects of the invention include combining the cement components to produce a settable composition. Aspects of the invention further include the settable compositions themselves as well as kits for preparing the same. Methods and compositions as described herein find use in a variety of applications, including hard tissue repair applications. | 2012-05-10 |
20120115781 | Methods For Evaluating and Implementing Prostate Disease Treatments - Provided is a method for evaluating test agents as candidates for treating prostatic diseases, including benign prostatic hyperplasia and androgen dependent and androgen independent prostate cancer. The method comprises providing a mouse comprising a human prostate primary xenograft, where the xenograft contains blood vessels that include human endothelial cells, initiating androgen deprivation in the mouse, administering to the mouse a test agent within a period of 1-7 days after initiating the androgen deprivation, and determining a reduction in human epithelial cells in the xenografts and/or a reduction in number of the endothelial cells or blood vessels in the xenograft. Also provided is a method for treating an individual for human prostate cancer or benign prostatic hyperplasia. The method comprises initiating androgen deprivation in the individual and administering to the individual an agent capable of inducing apoptosis of vascular endothelial cells within a period of 1-7 days of initiating androgen deprivation. | 2012-05-10 |
20120115782 | COMPOSITIONS AND METHODS FOR TREATING OR INHIBITING LIVER INJURY - The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. The invention also relates inter alia to methods of inhibiting or reducing the likelihood of liver injury secondary to hepatitis, cirrhosis and a number of other disease states and conditions and further may be used to reduce the likelihood of a patient at risk or treating a patient for inter alia hepatitis, cirrhosis, non-alcoholic fatty liver diseases (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis and other disease states and conditions as otherwise described. Pharmaceutical compositions are also described. | 2012-05-10 |
20120115783 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 2012-05-10 |
20120115784 | Assessment of Cardiac Health and Thrombotic Risk in a Patient - The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis. | 2012-05-10 |
20120115785 | ENDOTHELIAL NITRIC OXIDE SYNTHASE ANTAGONISTS AND USES THEREOF FOR INHIBITING OXYGEN TOXICITY - Compositions and methods for inhibiting the interaction between eNOS and β-actin are provided for use in inhibiting or reducing lung injury from oxygen toxicity. One embodiment provides a synthetic or recombinant polypeptide having the β-actin binding domain of eNOS, wherein the polypeptide inhibits or reduces eNOS activity in lung endothelial cells. | 2012-05-10 |
20120115786 | AGENT FOR REDUCING RISK IN ONSET OF DISEASE ASCRIBABLE TO NON-DIPPER CIRCADIAN RHYTHM OF BLOOD PRESSURE - An agent for reducing risk in onset of diseases ascribable to non-dipping circadian profile of blood pressure is provided. This agent is capable of effectively lowering SBP from night to early morning in individuals with non-dipping circadian profile of blood pressure, in particular, normal individuals with normal SBP and DBP among them, and is thus capable of reducing risk in onset, particularly likely in the morning, of diseases caused by circadian variation of blood pressure. The agent is intended for administration to such subjects, and contains a hydrolysate or a concentrate thereof, containing Val-Pro-Pro and Ile-Pro-Pro and obtained by hydrolysis of animal milk protein. Reduction of risk may be expected in onset, particularly likely in the morning, of various diseases caused by risk of circadian variation of blood pressure, such as cerebral infarction, myocardial infarction,myocardialischemia, atherosclerosis, cardiac failure, cerebral stroke, coronary artery diseases, and peripheral vascular diseases. | 2012-05-10 |
20120115787 | Sclerostin and the inhibition of WNT signaling and bone formation - The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass (HBM). In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt coreceptor LRP5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transducing canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at the late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the HBM phenotype associated with the loss of sclerostin may at least in part be attributed to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism. | 2012-05-10 |
20120115788 | Use of liposomal WNT composition to enhance Osseointegration - Methods and compositions are provided for the therapeutic use of Wnt proteins, for enhancing bone growth and regeneration, including repair following injury, osseointegration of implants, and the like. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain conditions it is desirable to provide Wnt activity for short periods of time, and an effective dose will be administered over a defined, short period of time. | 2012-05-10 |
20120115789 | Methylglyoxal-Scavenging Compounds and Their Use for the Prevention and Treatment of Pain and/or Hyperalgesia - The present invention relates to compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine- containing protein, preferably an arginine- or lysine-containing cellular protein, such as a sodium ion channel, e.g. the sodium ion channel Na(v)1.8. Preferred scavenger compounds are peptides comprising several or multiple repeats of the amino acid sequence motif Gly-Glu-X-Pro (GEXP), wherein X is Arg or Lys, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the compounds as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the compounds for the prevention and/or treatment of pain, hyperalgesia and pain related diseases, in particular pain and/or hyperalgesia caused by or associated with methylglyoxal and/or reactive carbonyl species (RCS). | 2012-05-10 |
20120115790 | THERAPEUTIC APPROACH TO NEURODEGENERATIVE DISORDERS USING A TFP5-PEPTIDE - Disclosed herein are isolated peptides, pharmaceutical compositions and methods for use of such for treating subjects with a neurodegenerative disease, such as Alzheimer's. In an example, an isolated polypeptide includes a cyclin dependent kinase 5 (Cdk5) inhibitory domain that has at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, wherein the Cdk5 inhibitory domain is linked to a protein transduction domain. Methods of reducing or inhibiting one or more symptoms associated with a neurodegenerative disease by administering a therapeutically effective amount of a pharmaceutical composition including one or more disclosed peptides are also provided. | 2012-05-10 |
20120115791 | Methods for Treating Immune Mediated Neurological Diseases - Polypeptides and other compounds that can bind specifically to the C | 2012-05-10 |
20120115792 | Method For The Treatment Of Infraorbital Dark Circles Using Botulinum Toxins - Infraorbital dark circles can be treated by administration of a botulinum toxin to a patient. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of an eye of a patient with infraorbital dark circles. | 2012-05-10 |
20120115793 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 2012-05-10 |
20120115794 | USE OF CD44V6 IN THE TREATMENT OF OPHTHALMIC DISEASES - The present invention relates to the use of peptide compounds for the prevention and/or treatment of ophthalmic diseases. In particular, the present invention relates to a peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 (KEQWFGNRWHEGYR) or of SEQ ID NO: 1 (KEKWFENEWQGKNP), or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatmend of an ophthalmic disease in an individual. While SEQ ID NO: 2 is a part of the human CD44v6, SEQ ID NO: 1 is a part of the rat CD44v6. | 2012-05-10 |
20120115795 | Regulation of Sodium Channels by PLUNC Proteins - The present invention relates to the ability of PLUNC proteins, such as SPLUNC1 and SPLUNC2, to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of PLUNC proteins to sodium channels. | 2012-05-10 |
20120115796 | Novel Spacer Moiety for Poly(ehtylene Glycol) Modified Peptide Based Compounds - The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure: | 2012-05-10 |
20120115797 | PEPTIDE COMPOSITIONS THAT DOWNREGULATE TLR-4 SIGNALING PATHWAY AND METHODS OF PRODUCING AND USING SAME - Compositions that include isolated peptides that inhibit TLR-4 signaling pathways and inflammation are disclosed. Methods of producing and using the compositions to inhibit TLR-4 signaling and/or inflammation are also disclosed herein. | 2012-05-10 |
20120115798 | METHOD FOR IMPROVING THE IMMUNITY OF A COMPANION ANIMAL - A method of improving the immunity of a companion animal. The method can include administering to the companion animal a glucose anti-metabolite. The glucose anti-metabolite can be 2-deoxy-D-glucose; 5-thio-D-glucose; 3-O-methylglucose; 1,5-anhydro-D-glucitol; 2,5-anhydro-D-glucitol; 2,5-anhydro-D-mannitol; mannoheptulose; and mixtures and combinations thereof. The companion animal can be a dog or a cat. Improving the immunity can include altering the proliferative ability of T and B immune cells, and altering the relative distribution of immune cell phenotypes, for example. | 2012-05-10 |
20120115799 | PHARMACEUTICAL FORMULATIONS - The present invention relates to formulations including compounds of Formula (I), | 2012-05-10 |
20120115800 | Pigment Aggregates - The invention provides a method for in vitro formation of anthocyanic vacuolar inclusion (AVD-like structures, the method comprising the step of combining at least one anthocyanin, and b) at least one lipid. The invention also provides AVI-like structures produced by the method of the invention, compositions comprising such AVI-like structures, and uses of such AVI-like structures. | 2012-05-10 |
20120115801 | METHOD FOR OBTAINING A STABLE DISPERSION OF BENZOYL PEROXIDE - Powder containing benzoyl peroxide is readily wetted by contacting the powder with a liquid containing one or more of a polyol, a polyol, ether, and a low-carbon organic alcohol. | 2012-05-10 |
20120115802 | Method for using ulipristal acetate with cytochrome isozyme modulators - The invention relates to a method of using ulipristal acetate or a metabolite thereof for providing contraception or for treating a patient's condition, comprising providing a patient with ulipristal acetate or a metabolite thereof, and informing the patient or a medical care worker that ulipristal acetate or a metabolite thereof affects activity of a cytochrome p450 isozyme, and that administration of ulipristal acetate or a metabolite thereof with a substance that affects activity of a cytochrome p450 isozyme can affect plasma concentration, safety, efficacy or any combination thereof of ulipristal acetate or a metabolite thereof, the substance, or both. | 2012-05-10 |
20120115803 | TREATMENT OF ACINETOBACTER WITH ALGINATE OLIGOMERS AND ANTIBIOTICS - The invention provides a method to improve the efficacy of an antibiotic to inhibit the growth of | 2012-05-10 |
20120115804 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING NEOPLASIA - The invention features compositions and methods for characterizing the methylation status of the Vitamin D Receptor (VDR) in neoplasia (e.g., breast carcinoma), selecting an appropriate therapy, and treating the neoplasia (e.g., breast carcinoma). | 2012-05-10 |
20120115805 | USE OF AT LEAST ONE NUCLEIC ACID TO INFLUENCE THE NATURAL PIGMENTATION PROCESS - A method for influencing the natural pigmentation process of skin or appendages thereof, includes the step of topically contacting the skin or appendages thereof with at least one nucleic acid containing at least 55% guanine nucleotide. | 2012-05-10 |
20120115806 | Antitumor Combination Including Cabazitaxel and Capecitabine - The invention relates to a method of treatment of metastatic breast cancer in a patient progressing after a previous anthracycline and/or taxane treatment, said method comprising administering to said patient a combination of antitumor agents comprising cabazitaxel and capecitabine, wherein each of said antitumor agents, independently, may be in the form of a base, in the form of a pharmaceutically acceptable acid salt or in the form of a hydrate or solvate. | 2012-05-10 |
20120115807 | COMBINATION OF ALOVUDINE AND ZIDOVUDINE IN A MOLAR RATIO OF 1:100 TO 1:350 - Co-administration of alovudine and zidovudine at ratios considerably in excess of the prior art completely or substantially abolishes the mitochondrial toxicity of alovudine in mitochondrial DNA depletion experiments. The invention thus provides pharmaceutical compositions comprising alovudine and zidovudine in a molar ratio in the range 1:100 to 1:350 and methods for the treatment or prophylaxis of multiply resistant HIV comprising the simultaneous or consequential administration of alovudine and zidovudine in the characteristic molar ratio. | 2012-05-10 |
20120115808 | PHARMACOLOGICAL PREPARATION FOR TOPICAL USE CONTAINING N-PALMITOYL-VANILLAMIDE - The present invention relates to topical preparations containing N-palmitoyl-vanillamide having hyperalgesic activity. In particular, the invention relates to N-palmitoyl-vanillamide for use in the treatment of pathologies selected from: post-herpetic neuralgia, neuralgia of trigeminus, occipital neuralgia, dental neuralgia, glottopharyngeal neuralgia, uremic neuralgia, diabetic neuralgia, headache of different origin, neuropathic itch, neurogenic itch, uremic itch, vulvodinia, vulvar vestibulitis, ano-rectal pain and itch, balano-preputial pain and itch, painful urogenital disorders of dogs and cats, psoriasis-associated pruritus and pain, itching skin diseases (e.g. atopic dermatitis) in the human and veterinary field, muscular pain, pain of the tendon, osteoarthritis associated pain in humans, dogs and cats; painful eye diseases in the human and veterinary field, inflammatory pathologies of the oral cavity in the human and veterinary field. | 2012-05-10 |
20120115809 | USE OF AN ACYLATED OCTASACCHARIDE AS AN ANTITHROMBOTIC AGENT - The instant invention relates to the use of the octasaccharide of formula (I), wherein Ac represents an acetyl group: | 2012-05-10 |
20120115810 | SURGICAL COMPOSITIONS FOR REDUCING THE INCIDENCE OF ADHESIONS - A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulation containing the polysaccharide dextrin. | 2012-05-10 |
20120115811 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS - Provided herein are compounds of formula I: wherein A, B, X, R | 2012-05-10 |
20120115812 | SURFACE COATINGS FOR SKIN - The present invention relates to skin coating compositions and methods and, in particular, to coatings containing an active agent. In some embodiments, the coating may be applied to a skin surface and may be essentially colorless and transparent. In some aspects, the coating comprises a polymer and an active agent, and the polymer may be configured for sustained release of the active agent. In some aspects, the coating forms a barrier essentially impermeable to microorganisms yet permeable to water vapor. The coating may also be flexible and conformable to the surface. The coating may be applied to the skin using any suitable method. In some embodiments, the polymer and/or active agent are dissolved and/or suspended in a volatile solvent. In some embodiments, the volatile solvent may function as an antiseptic on skin. | 2012-05-10 |
20120115813 | BORON-CONTAINING SMALL MOLECULES - This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections. | 2012-05-10 |
20120115814 | Liquid Pharmaceutical Form Of Alkylphosphocholine And Method For Preparing Same - The inventions relates to a liquid pharmaceutical form containing an active ingredient alkylphosphocholines and a co-solvent system. The co-solvent system is mixture from hexylene glycol, propylene glycol, diethylene glycol monoethyl ether and water. The pharmaceutical form having a pH value in the range of 4 to 6, which if it is necessary can be achieved by adding a pH adjuster. The composition has a good storage stability and it is suitable for local application on the different organs of the body. The inventions relates also to a method for producing the same pharmaceutical form. | 2012-05-10 |
20120115815 | COMPOSITIONS USEFUL ESPECIALLY FOR TREATMENT OR PREVENTION OF METABOLIC SYNDROME - This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier. | 2012-05-10 |
20120115816 | COMPATIBILIZED ELECTROLYTE FORMULATIONS - The invention includes aqueous compatibilized pesticidal formulations and methods of making them. In typical embodiments, formulations comprise a first electrolytic pesticide and a second electrolytic pesticide, and about 30 to about 300 g/L of at least one alkyl polyglycoside. The invention also includes methods of preparing pesticidal formulations to increase the concentration of the electrolytic pesticides. The invention also includes storage and transport systems containing formulation embodiments. The invention also includes methods inhibiting pests. | 2012-05-10 |
20120115817 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES - The present invention relates to phthalimide derivatives of non-steroidal and/or TNF-α modulating anti-inflammatory compounds as well as the process of obtaining the so-called derivatives, pharmaceutical compositions containing such derivatives and their uses, including use in the treatment of inflammatory diseases, especially those related to chronic inflammatory processes, such as rheumatoid arthritis and intestinal inflammatory diseases (for instance, Chron's disease) and the use of the referred to pharmaceutical compositions as antipyretic, analgesic and platelet antiaggregating medications. | 2012-05-10 |
20120115818 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO - Efficient method for preparing the enone intermediate (VII) used in the synthesis of tetracyclines derivatives. In particular, the invention provides a synthesis which allows for substituents at positions 4 | 2012-05-10 |
20120115819 | Pentacycline Compounds - The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use. | 2012-05-10 |
20120115820 | ACID PUMP ANTAGONIST FOR THE TREATMENT OF DISEASES INVOLVED IN ABNORMAL GASTROINTESTINAL MOTILITY - The present invention relates to a use of a compound having an acid pump antagonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for prevention or treatment of diseases in which abnormal gastrointestinal motility is involved. In addition, the present invention relates to the method of prevention or treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agent. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound having an acid pump antagonistic activity or a pharmaceutically acceptable salt thereof for the prevention or treatment of said diseases. | 2012-05-10 |